Diabetes, Obesity and Metabolism

Cover image for Vol. 18 Issue 2

Accepted Articles (Accepted, unedited articles published online and citable. The final edited and typeset version of record will appear in future.)

Edited By: R. Donnelly and A. Garber

Impact Factor: 6.36

ISI Journal Citation Reports © Ranking: 2014: 14/128 (Endocrinology & Metabolism)

Online ISSN: 1463-1326

VIEW

  1. 1 - 15
  1. LETTER TO THE EDITOR

    1. Gliptins-mediated neuroprotection against stroke requires chronic pre-treatment and is glucagon-like peptide-1 receptor independent

      Vladimer Darsalia, Martin Larsson, Grazyna Lietzau, David Nathanson, Thomas Nyström, Thomas Klein and Cesare Patrone

      Accepted manuscript online: 5 FEB 2016 01:14AM EST | DOI: 10.1111/dom.12641

  2. RESEARCH LETTERS

    1. Low Incidence of Anti-Drug Antibodies in Type 2 Diabetes Patients Treated with Once Weekly GLP-1 Receptor Agonist Dulaglutide

      Zvonko Milicevic, Greg Anglin, Kristine Harper, Robert J. Konrad, Zachary Skrivanek, Wolfgang Glaesner, Chrisanthi A. Karanikas and Kenneth Mace

      Accepted manuscript online: 5 FEB 2016 01:13AM EST | DOI: 10.1111/dom.12640

  3. ORIGINAL ARTICLES

    1. Exposure–response analyses of liraglutide 3.0 mg for weight management

      J. P. H. Wilding, R. V. Overgaard, L. Vestergård Jacobsen, Christine Bjørn Jensen and Carel W. le Roux

      Accepted manuscript online: 2 FEB 2016 02:11AM EST | DOI: 10.1111/dom.12639

  4. REVIEW ARTICLES

    1. The Therapeutic Potential of TGR5 Agonists. Hope or Hype?

      Rebecca J. Hodge and Derek J. Nunez

      Accepted manuscript online: 27 JAN 2016 10:03PM EST | DOI: 10.1111/dom.12636

    2. Effect of antibiotics on gut microbiota, glucose metabolism and bodyweight regulation - a review of the literature

      Kristian Hallundbæk Mikkelsen, Kristine Højgaard Allin and Filip Krag Knop

      Accepted manuscript online: 27 JAN 2016 10:03PM EST | DOI: 10.1111/dom.12637

  5. ORIGINAL ARTICLES

    1. Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11beta-HSD1 inhibitor in humans: Liver and adipose tissue 11beta-HSD1 inhibition after acute and multiple administrations over 2 weeks

      Susanna Freude, Tim Heise, Hans-Jürgen Wörle, Arvid Jungnik, Thomas Rauch, Bradford Hamilton, Corinna Schölch, Fenglei Huang and Ulrike Gräfe-Mody

      Accepted manuscript online: 22 JAN 2016 02:17AM EST | DOI: 10.1111/dom.12635

    2. You have full text access to this OnlineOpen article
      A 24-week Study to Evaluate the Efficacy and Safety of Once Weekly Dulaglutide Added on to Glimepiride in Type 2 Diabetes (AWARD-8)

      K. M. Dungan, R. Weitgasser, F. Perez Manghi, E. Pintilei, J. L. Fahrbach, H.H. Jiang, J. Shell and K.E. Robertson

      Accepted manuscript online: 22 JAN 2016 02:17AM EST | DOI: 10.1111/dom.12634

  6. RESEARCH LETTERS

    1. You have full text access to this OnlineOpen article
      Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: A 24-week multicenter, randomized, double-blind, placebo-controlled phase III trial

      Sangmo Hong, Cheol-Young Park, Kyung Ah Han, Choon Hee Chung, Bon Jeong Ku, Hak Chul Jang, Chul Woo Ahn, Moon-Kyu Lee, Min Kyong Moon, Hyun Shik Son, Chang Beom Lee, Yong-Wook Cho and Sung-Woo Park

      Accepted manuscript online: 9 JAN 2016 04:41AM EST | DOI: 10.1111/dom.12631

  7. ORIGINAL ARTICLES

    1. The effect of ranolazine on glycemic control in patients with type 2 diabetes treated with either glimepiride or metformin

      Jeremy Pettus, Brian McNabb, Robert H. Eckel, Jay S. Skyler, Arvinder Dhalla, Shanhong Guan, Philip Jochelson, Luiz Belardinelli and Robert H. Henry

      Accepted manuscript online: 8 JAN 2016 02:50AM EST | DOI: 10.1111/dom.12629

  8. RESEARCH LETTERS

    1. You have full text access to this OnlineOpen article
      The efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine

      I. Hadjiyianni, D. Dahl, L.B. Lacaya, R.K. Pollom, C. L. Chang and L.L. Ilag

      Accepted manuscript online: 7 JAN 2016 09:11PM EST | DOI: 10.1111/dom.12628

    2. The efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: Subgroup analysis across SCALE and phase 2 randomized trials

      J. Ard, A. Cannon, C.E. Lewis, H. Lofton, T. Vang Skjøth, B. Stevenin, X. Pi-Sunyer and on behalf of the Satiety Clinical Adiposity – Liraglutide Evidence in non-diabetic diabetic individuals (SCALE) study groups.

      Accepted manuscript online: 7 JAN 2016 08:34AM EST | DOI: 10.1111/dom.12632

  9. ORIGINAL ARTICLES

    1. Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes

      Ajenthen Ranjan, Signe Schmidt, Sten Madsbad, Jens Juul Holst and Kirsten Nørgaard

      Accepted manuscript online: 7 JAN 2016 08:01AM EST | DOI: 10.1111/dom.12627

  10. INVITED REVIEW ARTICLES

    1. Diabetic nephropathy - where are we on the journey from pathophysiology to treatment?

      H Gallagher and RJ Suckling

      Accepted manuscript online: 7 JAN 2016 08:01AM EST | DOI: 10.1111/dom.12630

  11. ORIGINAL ARTICLES

    1. You have full text access to this OnlineOpen article
      Clinical inertia in intensifying therapy among people with type 2 diabetes treated with basal insulin

      Kamlesh Khunti, Annie Nikolajsen, Brian L. Thorsted, Marc Andersen, Melanie J. Davies and Sanjoy K. Paul

      Accepted manuscript online: 7 JAN 2016 07:56AM EST | DOI: 10.1111/dom.12626

  12. RESEARCH LETTERS

    1. You have full text access to this OnlineOpen article
      Insulin degludec does not increase antibody formation versus insulin glargine: an evaluation of phase 3a trials

      Jiten Vora, Jochen Seufert, Helene Solberg, Ona Kinduryte, Thue Johansen and Priscilla Hollander

      Accepted manuscript online: 11 DEC 2015 02:28AM EST | DOI: 10.1111/dom.12621

VIEW

  1. 1 - 15

SEARCH

SEARCH BY CITATION